Compugen (CGEN)

1,389
-21(-1.49%)
  • Volume:
    114,097
  • Bid/Ask:
    1,399/1,404
  • Day's Range:
    1,350 - 1,417
  • Type:Equity
  • Market:Israel
  • ISIN:IL0010852080
  • S/N:1085208

CGEN Overview

Prev. Close
1,410
Day's Range
1,350-1,417
Revenue
25.3M
Open
1,410
52 wk Range
1,262-4,888
EPS
-1.27
Volume
114,097
Market Cap
1.2B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
116,727
P/E Ratio
-
Beta
1.6
1-Year Change
-65.23%
Shares Outstanding
86,214,105
Next Earnings Date
Feb 24, 2022
What is your sentiment on Compugen?
or
Market is currently closed. Voting is open during market hours.

Compugen Company Profile

Employees
68
Market
Israel

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellSellStrong Sell
Technical IndicatorsBuyStrong SellBuySellStrong Sell
SummaryBuyNeutralNeutralSellStrong Sell
  • Currently being valued ~315M counting cash on hand and no debt.
    0
    • Well my prediction came true and my $12 order filled today. Immediately it jumped up and I am up over 3% same day. Hoping this follows through with my prediction that it will be going up from here to $15!
      0
      • So wrong I was. Entire market crashed lol
        0
    • Falling wedge pattern. If it doesn't break out now, will fall back down to $12. Buy it then! Good chance it will sky rocket to $15 or more.
      0
      • any news?
        0
        • with a buy stop above $16, short around $13.50-$14. GL
          1
          • Really hope you didn't short
            0
        • Amazing news to come. The stock is about to fly very high.
          2
          • Looking strong on trend as etf’s are buying up this stock in large amounts
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.